- Home
- SUPN vs LMB Comparison
SUPN vs LMB Comparison
Compare SUPN & LMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- LMB
- Stock Information
- Founded
- SUPN 2005
- LMB 1901
- Country
- SUPN United States
- LMB United States
- Employees
- SUPN N/A
- LMB N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- LMB Engineering & Construction
- Sector
- SUPN Health Care
- LMB Consumer Discretionary
- Exchange
- SUPN Nasdaq
- LMB Nasdaq
- Market Cap
- SUPN 1.8B
- LMB 1.6B
- IPO Year
- SUPN 2012
- LMB 2014
- Fundamental
- Price
- SUPN $32.46
- LMB $145.62
- Analyst Decision
- SUPN Hold
- LMB Strong Buy
- Analyst Count
- SUPN 2
- LMB 3
- Target Price
- SUPN $36.00
- LMB $136.67
- AVG Volume (30 Days)
- SUPN 747.3K
- LMB 196.0K
- Earning Date
- SUPN 08-05-2025
- LMB 08-05-2025
- Dividend Yield
- SUPN N/A
- LMB N/A
- EPS Growth
- SUPN N/A
- LMB 31.50
- EPS
- SUPN 1.11
- LMB 2.78
- Revenue
- SUPN $667,997,000.00
- LMB $532,913,000.00
- Revenue This Year
- SUPN N/A
- LMB $20.01
- Revenue Next Year
- SUPN $12.02
- LMB $5.84
- P/E Ratio
- SUPN $29.24
- LMB $52.30
- Revenue Growth
- SUPN 11.82
- LMB 3.62
- 52 Week Low
- SUPN $25.94
- LMB $48.17
- 52 Week High
- SUPN $40.28
- LMB $154.05
- Technical
- Relative Strength Index (RSI)
- SUPN 53.20
- LMB 59.79
- Support Level
- SUPN $31.35
- LMB $139.79
- Resistance Level
- SUPN $32.55
- LMB $154.05
- Average True Range (ATR)
- SUPN 0.91
- LMB 5.60
- MACD
- SUPN 0.04
- LMB -0.28
- Stochastic Oscillator
- SUPN 60.93
- LMB 59.11
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.